Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2016-06-20 (9 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: PLOZEVET (29710), Finistere
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
SELARL PHARMACIE PRIJAC : revenue, balance sheet and financial ratios
SELARL PHARMACIE PRIJAC is a French company
founded 9 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in PLOZEVET (29710),
this company of category PME
shows in 2024 a net income positive of 182 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE PRIJAC (SIREN 821079753)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
181 996 €
190 475 €
195 920 €
195 748 €
174 598 €
164 885 €
178 258 €
38 989 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMACIE PRIJAC generates positive net income of 182 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2017-2024: 39 k€ -> 182 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
181 996 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 57%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
57.176%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
58.422%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
2084.369
668.81
372.311
240.396
161.874
115.643
79.925
57.176
Financial autonomy
4.199
11.888
19.812
27.651
34.83
42.707
50.897
58.422
Repayment capacity
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
57.182024
2022
2023
2024
Q1: 16.45
Med: 58.41
Q3: 154.59
Good-10 pts over 3 years
In 2024, the debt ratio of SELARL PHARMACIE PRIJAC (57.18) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
Financial autonomy
58.42%2024
2022
2023
2024
Q1: 28.92%
Med: 49.95%
Q3: 69.49%
Good+17 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE PRIJAC (58.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 229.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
223.394
218.975
291.831
322.616
251.646
287.596
217.973
229.541
Interest coverage
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
229.542024
2022
2023
2024
Q1: 129.47
Med: 182.14
Q3: 260.79
Good-10 pts over 3 years
In 2024, the liquidity ratio of SELARL PHARMACIE PRIJAC (229.54) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Positioning of SELARL PHARMACIE PRIJAC in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE PRIJAC is estimated at
2 540 798 €
(range 1 769 372€ - 3 801 180€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
1769k€2540k€3801k€
2 540 798 €Range: 1 769 372€ - 3 801 180€
NAF 5 année 2024
Valuation method used
Net Income Multiple
181 996 €
×
14.0x
=2 540 799 €
Range: 1 769 372€ - 3 801 180€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE PRIJAC with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE PRIJAC
What is the revenue of SELARL PHARMACIE PRIJAC ?
The revenue of SELARL PHARMACIE PRIJAC is not publicly disclosed (confidential accounts filed with INPI).
Is SELARL PHARMACIE PRIJAC profitable?
Yes, SELARL PHARMACIE PRIJAC generated a net profit of 182 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE PRIJAC ?
The headquarters of SELARL PHARMACIE PRIJAC is located in PLOZEVET (29710), in the department Finistere.
Where to find the tax return of SELARL PHARMACIE PRIJAC ?
The tax return of SELARL PHARMACIE PRIJAC is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE PRIJAC operate?
SELARL PHARMACIE PRIJAC operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart